Research suggests fund managers' biggest bets outperform. That’s even true for managers of poorly performing funds, although at the Investors' Chronicle, we’re only interested in the best of the best.
Every week, we publish a list of the “best ideas” of top fund managers from one of seven sectors. This week it is the turn of pharma, biotech and healthcare stocks.
Our fund managers’ best ideas tables constitute the top five holdings of a selection of top performing funds. The data is based on the funds’ most recent portfolio disclosures to Morningstar.
| FUND BEST IDEAS: HEALTH | |
| 10/5/2022 | No. Funds |
| AstraZeneca PLC | 6 (+1) |
| UnitedHealth Group Inc | 5 |
| Roche Holding AG | 4 (+1) |
| AbbVie Inc | 3 |
| Gilead Sciences Inc | 3 (+1) |
| Regeneron Pharmaceuticals Inc | 3 (+1) |
| Thermo Fisher Scientific Inc | 3 |
| Vertex Pharmaceuticals Inc | 3 |
| Amgen Inc | 2 |
| Eli Lilly and Co | 2 (+1) |
| Horizon Therapeutics PLC | 2 |
| Pfizer Inc | 2 (+1) |
| Abbott Laboratories | 1 (-2) |
| Biohaven Pharmaceutical Holding Co Ltd | 1 |
| Biomarin Pharmaceutical Inc | 1 (NEW) |
| Boston Scientific Corp | 1 |
| Bristol-Myers Squibb Co | 1 |
| CVS Health Corp | 1 |
| Cytokinetics Inc | 1 |
| Danaher Corp | 1 |
| Edwards Lifesciences Corp | 1 |
| Exelixis Inc | 1 |
| GH Research PLC | 1 |
| Illumina Inc | 1 |
| Intuitive Surgical Inc | 1 |
| Johnson & Johnson | 1 |
| Medtronic PLC | 1 |
| Seagen Inc Ordinary Shares | 1 |
| Stryker Corp | 1 |
| Uniphar PLC | 1 |
| Stryker Corp | 1 |
| Uniphar | 1 |
Source: Morningstar
Learn from the best
Understanding the investment process of some of the world's top fund managers can help private investors when they're picking stocks and when they're choosing which funds to invest in. In the links below you can listen to our discussions with some of the UK's best and head to our podcast page to listen to all our fund manager interviews.
Nick Train hates selling companies so much that he can’t quite remember which stock he sold last. “Selling is an admission you’ve made a mistake,” he says in this interview with Leonora Walters.
Walter Price: "The Chinese are a force to be reckoned with in technology"
Walter Price, portfolio manager of hugely successful Allianz Technology Trust, is concerned about the valuations of US tech companies. In this podcast, he tells us his views on growth, regulation, and China.
Roddy Snell: “I’ve rarely been so bullish on Asia”
Tension between the US and China isn’t something that worries Roddy Snell, co-manager at Baillie Gifford’s China Fund, Emerging Markets Leading Companies Fund and Pacific Fund.
